Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 87

Sort by

Sort Order Select

Journal Articles

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

Blood (2024) 144 (22): 2295–2307.

https://doi.org/10.1182/blood.2024024789

Published: 2024

Includes: Supplemental data

Journal Articles

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Joseph Pidala, Shernan G. Holtan, Kelly Walton, Jongphil Kim, Hany Elmariah, Asmita Mishra, Nelli Bejanyan, Taiga Nishihori, Farhad Khimani, Lia Perez, Rawan Faramand, Marco Davila, Claudio Anasetti, Daniel Weisdorf, Bruce R Blazar, Jeffrey S Miller, Veronika Bachanova, Najla H El Jurdi, Brian C Betts

Blood (2023) 142 (Supplement 1): 2177.

https://doi.org/10.1182/blood-2023-173376

Published: 2023

Journal Articles

Progress in risk-adapted acute GVHD therapy

Joseph Pidala

Blood (2023) 141 (5): 443–444.

https://doi.org/10.1182/blood.2022018021

Published: 2023

Journal Articles

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Nosha Farhadfar, Zeina Al-Mansour, Tao Wang, Karen Chen, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephen R. Spellman, John R. Wingard, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 5108–5109.

https://doi.org/10.1182/blood-2022-163537

Published: 2022

Journal Articles

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Caden Ulschmid, Xiao Li, Tao Wang, Brent Logan, Joseph Pidala, Margaret L. MacMillan, Carrie Lynn Kitko, Stephanie J. Lee, Stephen R. Spellman, Wael Saber

Blood (2022) 140 (Supplement 1): 279–281.

https://doi.org/10.1182/blood-2022-163263

Published: 2022

Journal Articles

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Omar Albanyan, Syeda Mahrukh Hussnain Naqvi, Qianxing Mo, Athena Belfon, Eric Gaskill, Taiga Nishihori, Rawan Faramand, Aleksandr Lazaryan, Doris K. Hansen, Farhad Khimani, Asmita Mishra, Michael Nieder, Lia Perez, Hien D. Liu, Joseph Pidala, Claudio Anasetti, Frederick L. Locke, Nelli Bejanyan, Hany Elmariah

Blood (2022) 140 (Supplement 1): 7664–7666.

https://doi.org/10.1182/blood-2022-166008

Published: 2022

Journal Articles

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Hassaan Yasin, Mahrukh Naqvi, Jongphil Kim, Rawan Faramand, Omar Alexis Castaneda Puglianini, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Michael Nieder, Joseph Pidala, Nelli Bejanyan

Blood (2022) 140 (Supplement 1): 4886–4888.

https://doi.org/10.1182/blood-2022-170696

Published: 2022

Journal Articles

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Blood (2022) 140 (Supplement 1): 886–888.

https://doi.org/10.1182/blood-2022-168175

Published: 2022

Journal Articles

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Filip Ionescu, David A. Sallman, Kendra Sweet, Rami S. Komrokji, Onyee Chan, Andrew Kuykendall, Eric Padron, Rawan Faramand, Nelli Bejanyan, Farhad Khimani, Hany Elmariah, Joseph Pidala, Asmita Mishra, Lia Perez, Taiga Nishihori, Jeffrey E. Lancet

Blood (2022) 140 (Supplement 1): 1288–1290.

https://doi.org/10.1182/blood-2022-165661

Published: 2022

Journal Articles

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease

Eric Gaskill, Maya Padilla, Rawan Faramand, Aleksandr Lazaryan, Farhad Khimani, Lia Perez, Joseph Pidala, Rebecca Gonzalez

Blood (2022) 140 (Supplement 1): 10512–10513.

https://doi.org/10.1182/blood-2022-167718

Published: 2022

Journal Articles

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

Blood (2022) 140 (Supplement 1): 10488–10490.

https://doi.org/10.1182/blood-2022-170337

Published: 2022

Journal Articles

The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease

Nahid Rashid, Mukta Arora, Paul A. Carpenter, Amin M Alousi, Betty K. Hamilton, Joseph Pidala, Lynn E. Onstad, Corey Cutler, Mary E.D. Flowers, Sally Arai, Smita Bhatia, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 10519–10520.

https://doi.org/10.1182/blood-2022-167901

Published: 2022

Journal Articles

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Blood (2022) 140 (Supplement 1): 7638–7640.

https://doi.org/10.1182/blood-2022-168400

Published: 2022

Journal Articles

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Stephanie Lee, Franco Locatelli, Francis A. Ayuk, Tsila Zuckerman, Kentaro Fukushima, Juan Carlos Vallejo Llamas, Joseph Pidala, Nada Hamad, Ivan S. Moiseev, Francesca Bonifazi, Shashikant Apte, Robert Zeiser, Valkal Bhatt, Maanasa Gowda, Jackie Han, Tommaso Stefanelli, Mike W. Zuurman, Takanori Teshima

Blood (2021) 138 (Supplement 1): 3909.

https://doi.org/10.1182/blood-2021-144576

Published: 2021

Journal Articles

Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?

Whitney Wallis, Alison Gulbis, Tao Wang, Karen Chen, Carrie Lynn Kitko, Margaret L. MacMillan, Joseph Pidala, Marcie L. Riches, Stephen R. Spellman, Mukta Arora, Amin M. Alousi

Blood (2021) 138 (Supplement 1): 2870.

https://doi.org/10.1182/blood-2021-148890

Published: 2021

Journal Articles

Association between CYP3A4, CYP3A5, and ABCB1 Genotype, Tacrolimus Concentrations, and Outcomes Among Allogeneic Hematopoietic Stem Cell Transplantation Patients

Teresa Ho, Janelle Perkins, Rebecca Gonzalez, J Kevin Hicks, Taiga Nishihori, Nelli Bejanyan, Joseph Pidala, Hany Elmariah

Blood (2021) 138 (Supplement 1): 2882.

https://doi.org/10.1182/blood-2021-151770

Published: 2021

Journal Articles

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Giacomo Adoncecchi, MS, Ambuj Kumar, MD MPH, Rawan Faramand, MD, Hien D. Liu, MD, Farhad Khimani, MD, Asmita Mishra, MD, Michael Nieder, MD, Taiga Nishihori, MD, Lia Perez, MD, Joseph Pidala, MD, Claudio Anasetti, MD, Nelli Bejanyan, MD, Hany Elmariah, MDMS

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-141966

Published: 2020

Journal Articles

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Salman Otoukesh, MD, Hany Elmariah, MDMS, Dongyun Yang, PhD, Sally Mokhtari, PhD, Madiha Siraj, Haris Ali, MD, Krishnakar Mogili, Shukaib Arslan, MD, Taiga Nishihori, MD, Chatchada Karanes, MD, Joseph Pidala, MD, Ryotaro Nakamura, MD, Claudio Anasetti, MD, Stephen J. Forman, MD, Monzr M. Al Malki, MD, Nelli Bejanyan, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-143166

Published: 2020

Journal Articles

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-137677

Published: 2020

Journal Articles

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Joseph Pidala, MD, Kelly Walton, Hany Elmariah, MDMS, Jongphil Kim, PhD, Asmita Mishra, MD, Nelli Bejanyan, MD, Taiga Nishihori, MD, Farhad Khimani, MBBS, Lia Perez, MD, Rawan Faramand, MD, Marco L. Davila, MD PhD, Michael Nieder, MD, Nicholas Lawrence, PhD, Harshani Lawrence, PhD, Claudio Anasetti, MD, Said Sebti, PhD, Brian C. Betts, MD

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-133874

Published: 2020

NARROW

JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results

JAK2/mTOR Inhibition Fails to Prevent Acute Gvhd Despite Reduced Th1/Th17 Cells: Final Phase II Trial Results

Progress in risk-adapted acute GVHD therapy

Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis

Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant Outcomes for Acute Myeloid Leukemia

Similar Risk of Relapse and Survival with Post-Transplant Cyclophosphamide Compared to Standard Gvhd Prophylaxis after Allogeneic Hematopoietic Cell Transplantation for AML and MDS

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience

Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-Versus-Host Disease

Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience

The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease

Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide

Patient-Reported Outcomes (PROs) Among Patients With Steroid-Refractory or -Dependent Chronic Graft-vs-Host Disease (cGVHD) Randomized to Ruxolitinib (RUX) vs Best Available Therapy (BAT)

Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?

Association between CYP3A4, CYP3A5, and ABCB1 Genotype, Tacrolimus Concentrations, and Outcomes Among Allogeneic Hematopoietic Stem Cell Transplantation Patients

Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients

Clinical Impact of Cytokine Release Syndrome on Outcomes of Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide

Bridging the Gap in Access to Transplant for Underserved Minority Patients Using Mismatched Unrelated Donors and Post-Transplant Cyclophosphamide: A National Marrow Donor Program/be the Match (NMDP/BTM) Initiative

Biological and Clinical Impact of JAK2/mTOR Blockade in Gvhd Prevention: Preclinical and Phase I Trial Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only